Advertisement

Topics

Supernus Gains Epilepsy Drug through Acquisition of Biscayne Neurotherapeutics

09:55 EDT 14 Sep 2018 | Speciality Pharma Journal

ROCKVILLE, Md., Sept. 13, 2018 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it entered into a merger agreement to acquire Biscayne Neurotherapeutics (Biscayne), a privately-held company developing a novel treatment for epilepsy. Supernus will obtain worldwide rights (excluding …

Original Article: Supernus Gains Epilepsy Drug through Acquisition of Biscayne Neurotherapeutics

NEXT ARTICLE

More From BioPortfolio on "Supernus Gains Epilepsy Drug through Acquisition of Biscayne Neurotherapeutics"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...